Mergers & Acquisitions

Acquisition of aaaiPharma Products by branded pharmaceutical company complete

Published in Women's Health Weekly, August 25th, 2005

Xanodyne Pharmaceuticals, Inc., a privately held, specialty pharmaceutical company focusing on innovative products in the therapeutic areas of women's health and pain management, announced that it completed the transaction to acquire most of the assets of aaiPharma's pharmaceuticals division.

The deal terms included $209.25 million cash and additional non-cash consideration.

The acquired products include the Darvon and Darvocet brand families, Oramorph SR, Methadone Injection, Duraclon, Roxicodone, and Roxanol, as well as 4 new products in development. Xanodyne already has a solid presence in the women's health arena with its currently marketed...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2005-08-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry